UEG Week: Teva and Sanofi's Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn's Disease
*In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44*In CD, duvakitug maintained
